Daratumumab maintenance for AL amyloidosis after initial treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have confirmed AL amyloidosis (a specific protein type) with organ involvement that requires treatment at diagnosis
- Finish (or be scheduled to finish) 6 cycles of daratumumab plus CyBorD-type induction treatment, and only then start study treatment
- Have a good blood response after induction (complete response, very good partial response, or partial response with certain free-light-chain results and/or organ improvement)
- Have adequate blood counts (enough hemoglobin, neutrophils, and platelets) and be able to return for follow-up visits and questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.